Strides Pharma Science Limited — Updates, 30-01-2025: Press Release

Strides Pharma Science Ltd reported a robust performance for Q3 FY25, with revenue reaching ₹11,537 million, reflecting a growth of 14.6% year-on-year. Gross margins increased by 25.1% to ₹6,735 million, yielding a gross margin percentage of 58.4%. EBITDA surged 46.9% year-on-year to ₹2,103 million, with an EBITDA margin of 18.2%, marking an improvement of 401 basis points. The company's reported PAT stood at ₹900 million, leading to an EPS of ₹9.56.

The management expressed confidence in the outlook, having upgraded targets to the top end of the range. The U.S. business generated revenue of $73 million, with a 13.7% increase year-on-year, contributing to a cumulative $214 million for the first nine months of FY25. Strides' commitment to sustainability was highlighted with a strong ESG rating of 76/100. Notably, the board welcomed a new independent director, enhancing corporate governance as the company continues to focus on strategic growth initiatives. Positive outlook remains as they aim to capitalize on market opportunities moving forward.